{"hands_on_practices": [{"introduction": "The decision to proceed with a radical cystectomy, a life-altering operation, is one of the most critical judgments in urologic oncology. This exercise challenges you to move beyond simple staging rules and construct a formal decision algorithm for a patient with high-risk non-muscle-invasive bladder cancer. By synthesizing principles of tumor biology, field cancerization, and risk stratification, you will learn to rigorously justify the choice of radical surgery over bladder-sparing options, a foundational skill in surgical oncology [@problem_id:5089835].", "problem": "A patient with urothelial carcinoma of the bladder presents after a repeat Transurethral Resection of Bladder Tumor (TURBT) with multifocal high-grade stage $T1$ disease and concomitant carcinoma in situ (CIS). There are $n=4$ papillary lesions ranging from 2 to 3 cm, distributed over the posterior wall and lateral walls, and random biopsies demonstrate diffuse CIS. The lamina propria is invaded, muscularis propria is present and uninvolved, lymphovascular invasion is absent, and variant histology is not identified. The Eastern Cooperative Oncology Group (ECOG) performance status is $0$, the Charlson Comorbidity Index (CCI) is $3$, estimated glomerular filtration rate is $75$ $\\text{mL/min/1.73 m}^2$, and there is no urethral involvement on prostatic urethral biopsy. Imaging shows no nodal or distant metastasis. The patient is Bacillus Calmette-Guérin (BCG) naive.\n\nConstructing a decision algorithm must begin from first principles of tumor biology, staging, and comorbidity:\n\n- Tumor biology and field effect: carcinoma in situ (CIS) is a flat, high-grade, noninvasive lesion that reflects a diffuse “field cancerization” of the urothelium; multifocality indicates a widespread mucosal risk reservoir rather than a solitary clonal focus.\n- Tumor staging under the Tumor, Node, Metastasis (TNM) system: stage $T1$ denotes invasion into the lamina propria; high grade confers a substantial risk of progression to muscle-invasive disease and of occult understaging even when muscularis propria is sampled.\n- Oncologic adequacy of partial cystectomy: partial cystectomy requires a solitary, resectable lesion in a location permitting adequate margins and reconstruction, and critically, absence of diffuse mucosal disease such as CIS or multifocality, because mucosa retained will harbor and seed recurrence.\n- Surgical decision thresholds: if the estimated probability of progression to muscle-invasive disease within a clinically relevant horizon, $P_{\\text{progression}}$, exceeds a threshold $\\theta$ set by institutional policy balancing survival benefit and morbidity (e.g., $\\theta=0.40$), and if the patient is a surgical candidate (perioperative mortality risk $0.05$, acceptable CCI, adequate performance status), then radical cystectomy with pelvic lymphadenectomy and appropriate urinary diversion is favored over bladder-sparing surgery. \n- Basic probability principles: when multiple independent or positively correlated high-risk features are present (high grade $T1$, CIS, multifocality), the combined risk can be approximated conservatively via a union bound or multiplicatively if independence is assumed for a lower bound, acknowledging that exact independence does not strictly hold.\n\nAssume the following well-tested estimates from observational cohorts for high-risk non-muscle-invasive bladder cancer: baseline $T1$ high-grade progression risk at $5$ years $p_{T1}=0.30$, added risk attributable to concomitant CIS $p_{\\text{CIS}}=0.15$, and added risk from multifocality $p_{\\text{multi}}=0.10$. A conservative union bound gives $$P_{\\text{progression}} \\leq p_{T1} + p_{\\text{CIS}} + p_{\\text{multi}} = 0.55,$$ while a multiplicative complement model gives $$P_{\\text{progression}} \\geq 1-(1-p_{T1})(1-p_{\\text{CIS}})(1-p_{\\text{multi}}) = 1-(0.70)(0.85)(0.90) \\approx 0.4645.$$\n\nWhich of the following decision algorithms most correctly applies these first principles to justify choosing radical cystectomy over partial cystectomy for this patient?\n\nA. Stage-anchored bladder-sparing algorithm: Because the tumor is non-muscle-invasive ($T1$), mandate initial intravesical therapy; reserve radical cystectomy strictly for muscle-invasive ($T2$) or refractory disease; consider partial cystectomy if any lesion is accessible, irrespective of multifocality or CIS.\n\nB. Field-effect and risk-threshold algorithm: Exclude partial cystectomy on the basis of diffuse mucosal disease (multifocality and CIS) making oncologic completeness unattainable; estimate $P_{\\text{progression}}$ using conservative combination of high-risk features, finding $P_{\\text{progression}} \\in [0.4645,0.55] \\geq \\theta=0.40$; confirm surgical candidacy (ECOG $0$, CCI $3$, estimated perioperative mortality risk $0.05$, adequate renal function for diversion) and select radical cystectomy with pelvic lymphadenectomy and an orthotopic neobladder given absent urethral involvement.\n\nC. Comorbidity-minimization algorithm: Prefer the least invasive operation for any non-muscle-invasive disease; select partial cystectomy to remove macroscopic tumors and plan postoperative intravesical BCG to suppress CIS; disregard multifocality and CIS because intravesical therapy addresses mucosal disease; escalate only if intravesical therapy fails.\n\nD. Margin-centric algorithm: If a partial cystectomy can achieve a $2$ $\\text{cm}$ margin around each tumor, residual bladder capacity is adequate, and CCI is $5$, then partial cystectomy is appropriate even with CIS; reserve radical cystectomy for cases where margins are technically unattainable or the patient refuses intravesical therapy.\n\nE. Trimodality redirection algorithm: To avoid radical surgery in non-muscle-invasive disease, propose Transurethral Resection of Bladder Tumor (TURBT) plus concurrent chemoradiation, reserving radical cystectomy only for salvage; treat CIS with radiosensitizing chemotherapy; defer decision thresholds based on $P_{\\text{progression}}$ until after radiotherapy response assessment.\n\nSelect the single best option.", "solution": "The user has provided a clinical scenario and a set of explicit principles for decision-making and has tasked me with validating the problem and identifying the single best decision algorithm among the options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\nThe problem statement provides the following information:\n\n**Patient Clinical Data:**\n- Diagnosis: Urothelial carcinoma of the bladder\n- Pathology: Multifocal ($n=4$) high-grade stage $T1$ disease with concomitant carcinoma in situ (CIS).\n- Lesion characteristics: $2$ to $3$ $\\text{cm}$ papillary lesions on the posterior and lateral walls.\n- Histology details: Lamina propria invaded, muscularis propria present and not invaded, lymphovascular invasion is absent, no variant histology. Random biopsies show diffuse CIS.\n- Patient fitness: Eastern Cooperative Oncology Group (ECOG) performance status is $0$. Charlson Comorbidity Index (CCI) is $3$.\n- Renal function: Estimated glomerular filtration rate (eGFR) is $75$ $\\text{mL/min/1.73 m}^2$.\n- Urethral status: No urethral involvement on prostatic urethral biopsy.\n- Staging: No nodal or distant metastasis on imaging.\n- Treatment history: Bacillus Calmette-Guérin (BCG) naive.\n\n**Decision-Making Principles and Data:**\n- **Tumor biology and field effect:** CIS implies diffuse \"field cancerization\". Multifocality implies a widespread mucosal risk reservoir.\n- **Tumor staging (TNM):** Stage $T1$ is lamina propria invasion. High grade confers a substantial risk of progression.\n- **Oncologic adequacy of partial cystectomy:** This procedure requires a solitary, resectable lesion and the absence of diffuse mucosal disease like CIS or multifocality.\n- **Surgical decision thresholds:** Radical cystectomy is favored if the estimated probability of progression, $P_{\\text{progression}}$, exceeds a threshold $\\theta$ (e.g., $\\theta=0.40$), provided the patient is a surgical candidate (perioperative mortality risk $0.05$, acceptable CCI, adequate performance status).\n- **Probability principles  estimates:**\n    - Baseline 5-year progression risk for $T1$ high-grade: $p_{T1}=0.30$.\n    - Added risk from concomitant CIS: $p_{\\text{CIS}}=0.15$.\n    - Added risk from multifocality: $p_{\\text{multi}}=0.10$.\n    - Union bound calculation: $P_{\\text{progression}} \\leq p_{T1} + p_{\\text{CIS}} + p_{\\text{multi}} = 0.55$.\n    - Multiplicative complement model: $P_{\\text{progression}} \\geq 1-(1-p_{T1})(1-p_{\\text{CIS}})(1-p_{\\text{multi}}) \\approx 0.4645$.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem is evaluated against the validation criteria:\n\n- **Scientifically Grounded:** The problem is firmly grounded in the principles of urologic oncology. The patient presentation (high-risk non-muscle-invasive bladder cancer), staging ($T1$, CIS), risk factors (multifocality, high grade), patient assessment metrics (ECOG, CCI, eGFR), and treatment considerations (partial vs. radical cystectomy, intravesical therapy) are all standard and factual. The risk stratification and decision logic mirror established clinical guidelines (e.g., from the American Urological Association or European Association of Urology).\n- **Well-Posed:** The problem is well-posed. It provides a complete set of data and a coherent logical framework (the \"first principles\") and asks which of the provided options correctly applies this framework. This structure leads to a unique, derivable solution.\n- **Objective:** The language is clinical, precise, and free from subjective bias. All key parameters are quantified.\n- **Flaw Analysis:**\n    - No scientific or factual unsoundness is present.\n    - The problem is highly relevant to the specified topic and is formalizable.\n    - The setup is complete and internally consistent. The patient's good performance status (ECOG $0$) and moderate comorbidity (CCI $3$) make them a plausible candidate for the major surgery being considered.\n    - The scenario is clinically realistic.\n    - The problem is well-structured and not ill-posed.\n    - The problem is not trivial; it requires careful integration of multiple principles.\n    - The reasoning is based on verifiable clinical and statistical principles.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is a well-constructed, scientifically sound clinical reasoning problem. I will proceed with the detailed solution.\n\n### Derivation and Option Analysis\n\nThe solution must be derived by methodically applying the provided principles to the patient's data.\n\n**1. Application of the `Oncologic adequacy of partial cystectomy` Principle:**\nThis principle is the most direct and decisive for one part of the question. It states that partial cystectomy is appropriate only for a **solitary** lesion and requires the **absence of diffuse mucosal disease such as CIS or multifocality**.\n- The patient has **multifocal** disease ($n=4$ lesions).\n- The patient has diffuse **carcinoma in situ (CIS)**.\n- Therefore, based on this principle alone, partial cystectomy is oncologically contraindicated. Any algorithm proposing partial cystectomy for this patient is fundamentally flawed according to the problem's own rules.\n\n**2. Application of the `Surgical decision thresholds` and `Probability principles`:**\nThis set of principles determines whether immediate radical cystectomy is justified over a bladder-sparing approach (like intravesical BCG, the standard alternative for a BCG-naive patient).\n- The condition for favoring radical cystectomy is $P_{\\text{progression}}  \\theta$.\n- The problem provides the threshold $\\theta = 0.40$.\n- The problem provides the calculated range for the patient's 5-year progression risk: $P_{\\text{progression}}$ is within the interval $[0.4645, 0.55]$.\n- Since the lower bound of the estimated progression probability, $0.4645$, is greater than the decision threshold, $0.40$, the condition $P_{\\text{progression}}  \\theta$ is unequivocally met.\n\n**3. Assessment of Surgical Candidacy:**\nThe decision for radical cystectomy also depends on the patient being a surgical candidate.\n- The patient's ECOG performance status is $0$, indicating they are fully active and asymptomatic, which is an excellent status for undergoing major surgery.\n- The patient's Charlson Comorbidity Index (CCI) is $3$. While this indicates some comorbidities, it is generally considered an acceptable risk profile for radical cystectomy, especially when performance status is high. The principle requires an \"acceptable CCI\".\n- The perioperative mortality risk threshold is stated as $0.05$. A patient with ECOG $0$ and CCI $3$ would typically fall within this acceptable risk range at a high-volume center.\n- Thus, the patient qualifies as a surgical candidate.\n\n**4. Consideration of Urinary Diversion:**\nFor a patient undergoing radical cystectomy, the choice of urinary diversion is critical.\n- The patient has an eGFR of $75$ $\\text{mL/min/1.73 m}^2$, which is excellent renal function that does not preclude any type of diversion (ileal conduit, continent cutaneous pouch, or orthotopic neobladder).\n- The patient has no urethral involvement. This is a key prerequisite for considering an orthotopic neobladder, which allows for urination through the native urethra.\n- Therefore, an orthotopic neobladder is a highly appropriate diversion to consider.\n\n**Synthesis of the Correct Algorithm:**\nThe correct decision algorithm must first exclude partial cystectomy based on the principle of field cancerization (multifocality and CIS). Second, it must calculate or acknowledge the high progression risk, note that it exceeds the given threshold, and confirm the patient is a suitable surgical candidate. Finally, it should conclude that radical cystectomy with an appropriate urinary diversion (like an orthotopic neobladder, given the negative urethra) is the indicated treatment.\n\n### Evaluation of Options\n\n**A. Stage-anchored bladder-sparing algorithm:** This algorithm proposes considering partial cystectomy irrespective of multifocality or CIS. This directly violates the `Oncologic adequacy of partial cystectomy` principle. It also incorrectly suggests reserving radical surgery only for muscle-invasive disease, which contradicts the `Surgical decision thresholds` principle for high-risk non-muscle-invasive disease.\n**Verdict:** Incorrect.\n\n**B. Field-effect and risk-threshold algorithm:** This algorithm correctly follows the derived logic. It first excludes partial cystectomy due to multifocality and CIS (\"field-effect\"). It then correctly applies the risk threshold, noting that $P_{\\text{progression}} \\in [0.4645, 0.55]$ exceeds $\\theta=0.40$. It correctly confirms surgical candidacy based on ECOG and CCI. It concludes with radical cystectomy and pelvic lymphadenectomy, and appropriately suggests an orthotopic neobladder as a diversion option based on the lack of urethral involvement. This algorithm perfectly integrates all provided data and principles.\n**Verdict:** Correct.\n\n**C. Comorbidity-minimization algorithm:** This algorithm advocates for partial cystectomy, which has already been established as oncologically contraindicated by the problem's principles due to multifocality and CIS. It wrongly minimizes the significance of these high-risk features and relies on the unproven success of subsequent intravesical therapy in a very high-risk setting where the progression probability already exceeds the threshold for radical surgery.\n**Verdict:** Incorrect.\n\n**D. Margin-centric algorithm:** This algorithm suggests partial cystectomy is appropriate if surgical margins can be achieved, even with CIS. This is a fundamental misunderstanding of the principle of field cancerization. CIS is a diffuse mucosal disease; there are no \"margins\" for CIS in the way there are for a focal tumor. The presence of CIS is an explicit contraindication to partial cystectomy according to the problem's own rules.\n**Verdict:** Incorrect.\n\n**E. Trimodality redirection algorithm:** This algorithm proposes trimodality therapy (TURBT + chemoradiation). This modality is primarily an option for muscle-invasive bladder cancer ($T2$ and higher), not high-risk non-muscle-invasive disease ($T1$). The problem's principles frame the decision between surgical options and do not provide any basis for choosing chemoradiation in this context. It is an inappropriate redirection from the established decision framework.\n**Verdict:** Incorrect.", "answer": "$$\\boxed{B}$$", "id": "5089835"}, {"introduction": "Once the decision to operate is made, mastery of intraoperative physiology becomes paramount. Radical cystectomy with urinary diversion is a lengthy procedure associated with significant fluid shifts that can impact patient outcomes. This problem requires you to apply the principle of mass conservation to quantify a patient's net fluid balance and distinguish it from internal fluid sequestration, or 'third-spacing'. Accurately calculating these volumes [@problem_id:5089800] is a core competency for maintaining hemodynamic stability and ensuring optimal organ perfusion during major abdominal surgery.", "problem": "A patient with muscle-invasive bladder cancer undergoes an open radical cystectomy with ileal conduit urinary diversion under general anesthesia. The operation duration is 6 hours. The anesthesia record shows the following:\n- Crystalloids administered: 3500 mL\n- Urine output: 800 mL\n- Estimated blood loss: 700 mL\n- Estimated evaporative insensible loss (from open abdomen and respiration): 600 mL\n\nAssume no colloids or blood products are administered. The patient’s mass is 80 kg. For this class of major pelvic open surgery with enteric urinary reconstruction, assume an empirically observed intraoperative capillary leak/third-space sequestration rate of $3.0 \\, \\text{mL} \\cdot \\text{kg}^{-1} \\cdot \\text{h}^{-1}$.\n\nUsing conservation of mass in the fluid compartments, and taking third-space sequestration to represent internal redistribution (not an external loss), do the following:\n1) Compute the net cumulative intraoperative fluid balance (total body water change) as total inputs minus external measured outputs.\n2) Compute the estimated third-space sequestration volume over the case using the given rate.\n\nExpress both answers in mL. Round your answers to three significant figures.", "solution": "The problem statement is evaluated and found to be valid. It is scientifically grounded in the principles of perioperative fluid physiology, well-posed with sufficient and consistent data, and objectively stated. Therefore, a solution can be derived.\n\nThe problem asks for two calculations related to a patient's intraoperative fluid status: the net cumulative fluid balance and the estimated volume of third-space sequestration. We address these sequentially.\n\n1. Computation of Net Cumulative Intraoperative Fluid Balance\n\nThe net cumulative fluid balance represents the net change in the patient's total body water, which we denote as $\\Delta V_{TBW}$. According to the principle of conservation of mass, this change is the difference between the total volume of fluid inputs and the total volume of external fluid outputs.\n\nThe total fluid input, $V_{in}$, consists solely of the crystalloids administered:\n$$V_{in} = 3500 \\text{ mL}$$\n\nThe total external fluid output, $V_{out,ext}$, is the sum of all losses from the body to the environment. Based on the data provided, this includes urine output ($V_{urine}$), estimated blood loss ($V_{blood}$), and evaporative insensible losses ($V_{evap}$).\n$$V_{out,ext} = V_{urine} + V_{blood} + V_{evap}$$\nAs explicitly stated in the problem, third-space sequestration is an internal redistribution of fluid and not an external loss. Therefore, it is correctly excluded from this calculation.\n\nSubstituting the given numerical values:\n$$V_{out,ext} = 800 \\text{ mL} + 700 \\text{ mL} + 600 \\text{ mL} = 2100 \\text{ mL}$$\n\nThe net cumulative fluid balance is then calculated as:\n$$\\Delta V_{TBW} = V_{in} - V_{out,ext}$$\n$$\\Delta V_{TBW} = 3500 \\text{ mL} - 2100 \\text{ mL} = 1400 \\text{ mL}$$\nThe problem requires the answer to be rounded to three significant figures. The value $1400$ can be expressed in scientific notation as $1.40 \\times 10^3$, which confirms it has three significant figures. A positive balance indicates a net gain of fluid by the patient.\n\n2. Computation of Estimated Third-Space Sequestration Volume\n\nThe third-space sequestration volume, $V_{3s}$, is the estimated amount of fluid that has shifted from the functional intravascular axtravascular compartments to non-functional spaces, such as the interstitium of traumatized tissues or the lumen of the bowel. This volume is calculated based on the provided empirical rate, $R_{3s}$, the patient's mass, $m$, and the duration of the surgery, $t$.\n\nThe relationship is given by:\n$$V_{3s} = R_{3s} \\times m \\times t$$\n\nThe problem provides the following values:\n- Sequestration rate, $R_{3s} = 3.0 \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{h}}$\n- Patient mass, $m = 80 \\text{ kg}$\n- Operation duration, $t = 6 \\text{ h}$\n\nSubstituting these values into the equation:\n$$V_{3s} = \\left(3.0 \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{h}}\\right) \\times (80 \\text{ kg}) \\times (6 \\text{ h})$$\nThe dimensional analysis confirms the result will be in milliliters (mL), as the units of kilograms (kg) and hours (h) cancel out.\n$$V_{3s} = 240 \\frac{\\text{mL}}{\\text{h}} \\times 6 \\text{ h}$$\n$$V_{3s} = 1440 \\text{ mL}$$\nThe problem requires this answer to be rounded to three significant figures. The value $1440$ can be written as $1.44 \\times 10^3$, which has three significant figures. Thus, the estimated third-space sequestration volume is $1440$ mL.", "answer": "$$\\boxed{\\begin{pmatrix} 1400  1440 \\end{pmatrix}}$$", "id": "5089800"}, {"introduction": "The surgeon's responsibility extends far beyond the operating room, especially following the creation of a urinary diversion from an intestinal segment. This practice focuses on a classic postoperative challenge: the metabolic consequences of exposing intestinal mucosa to urine. You will analyze a common set of postoperative laboratory values to diagnose the resulting acid-base disorder and apply the physicochemical framework of the strong ion difference. This exercise [@problem_id:5089791] will deepen your understanding of the intricate link between surgical reconstruction and systemic physiology, which is essential for effective long-term patient management.", "problem": "A 62-year-old patient with muscle-invasive urothelial carcinoma underwent radical cystectomy with creation of an orthotopic ileal neobladder. On postoperative day $3$, laboratory values are: sodium $[\\text{Na}^{+}] = 132~\\text{mmol/L}$, chloride $[\\text{Cl}^{-}] = 112~\\text{mmol/L}$, bicarbonate $[\\text{HCO}_{3}^{-}] = 18~\\text{mmol/L}$, and creatinine $= 1.6~\\text{mg/dL}$. Arterial blood gas analysis shows a partial pressure of carbon dioxide $P_{\\text{a}\\text{CO}_{2}} = 40~\\text{mmHg}$ with a normal hemoglobin and albumin.\n\nUsing the physicochemical framework for acid-base analysis based on the principles of electroneutrality and water dissociation equilibria, first determine the primary acid-base disorder in this clinical context of urinary diversion with an intestinal segment. Then, using only the provided measured strong ions, compute the apparent strong ion difference, defined by the difference between the sum of measured fully dissociated cations and the sum of measured fully dissociated anions available from the provided data. Express your numerical answer for the apparent strong ion difference in $\\text{mmol/L}$ and round to three significant figures.", "solution": "We begin from the biophysical principles of acid-base chemistry in plasma:\n\n1. Electroneutrality: the sum of positive charges equals the sum of negative charges in solution. In plasma, this can be written conceptually as\n$$\n\\sum \\text{strong cations} + \\text{weak acid charges} = \\sum \\text{strong anions} + \\text{bicarbonate-related charges} + \\text{other weak base charges}.\n$$\n2. The Stewart strong ion approach recognizes that the independent variables governing acid-base status are: the strong ion difference (SID), total weak acids, and partial pressure of carbon dioxide $P_{\\text{CO}_{2}}$. A decrease in the strong ion difference reduces $[\\text{HCO}_{3}^{-}]$ and generates metabolic acidosis.\n\nIn the postoperative context of urinary diversion using an intestinal segment (ileal neobladder), chloride $[\\text{Cl}^{-}]$ and ammonium can be absorbed from urine contacting mucosa, often producing hyperchloremic metabolic acidosis characterized by reduced $[\\text{HCO}_{3}^{-}]$ without an increased unmeasured anion burden. The provided data show $[\\text{HCO}_{3}^{-}] = 18~\\text{mmol/L}$ and $P_{\\text{a}\\text{CO}_{2}} = 40~\\text{mmHg}$. A $P_{\\text{a}\\text{CO}_{2}}$ near the customary physiologic value supports the interpretation that the low bicarbonate reflects a primary metabolic process rather than a respiratory disturbance.\n\nDiagnosis of the primary acid-base disorder:\n- $[\\text{HCO}_{3}^{-}]$ is reduced ($18~\\text{mmol/L}$).\n- $[\\text{Cl}^{-}]$ is elevated ($112~\\text{mmol/L}$) relative to $[\\text{Na}^{+}] = 132~\\text{mmol/L}$.\n- $P_{\\text{a}\\text{CO}_{2}}$ is not reduced, which would be expected with primary respiratory alkalosis, nor elevated to explain the low bicarbonate via compensation. Thus, the pattern is consistent with hyperchloremic (normal-gap) metabolic acidosis, a well-known consequence of urinary intestinal diversion.\n\nComputation of the apparent strong ion difference from the measured strong ions:\nBy definition, the strong ion difference (SID) is the difference between the sum of fully dissociated cations and the sum of fully dissociated anions in plasma. When only sodium and chloride are available as measured strong ions, an apparent or simplified SID can be formed using these two:\n$$\n\\text{SID}_{\\text{app}} = [\\text{Na}^{+}] - [\\text{Cl}^{-}].\n$$\nSubstituting the provided values:\n$$\n\\text{SID}_{\\text{app}} = 132 - 112 = 20.\n$$\nThe unit is $\\text{mmol/L}$. Rounding to three significant figures gives $20.0$.\n\nInterpretation:\nA simplified $\\text{SID}_{\\text{app}}$ of $20.0~\\text{mmol/L}$ is lower than typical values when using $[\\text{Na}^{+}] - [\\text{Cl}^{-}]$ (often near the mid-$30$s), supporting the diagnosis of a strong ion–mediated metabolic acidosis driven by relative hyperchloremia following urinary diversion.\n\nTherefore, the apparent strong ion difference computed from the provided measured strong ions is $20.0~\\text{mmol/L}$ (rounded to three significant figures).", "answer": "$$\\boxed{20.0}$$", "id": "5089791"}]}